Home › Macular Degeneration › Florida › Sarasota
Macular Degeneration clinical trials in Sarasota, FL
4 studies for Macular Degeneration are looking for participants at sites in and around Sarasota (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Retina Group of Florida, RAS-Sarasota Retina Center-Ophthalmology, Sarasota
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Retina Group of Florida, Sarasota
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RecruitingPhase 2/3
- Retina Group of Florida (Site 065), Sarasota
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Recruiting
- Sarasota Retina Institute, Sarasota
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX13 studies
- Erie, PA10 studies
- The Woodlands, TX9 studies
- Sacramento, CA8 studies
- Hagerstown, MD8 studies
- Reno, NV8 studies
- Phoenix, AZ7 studies
- Cleveland, OH7 studies
- Houston, TX7 studies
- Salt Lake City, UT7 studies
- Boston, MA7 studies
- Austin, TX7 studies
Other studies in Sarasota
- Metastatic Cancer19 studies
- Non-Small Cell Lung Cancer17 studies
- Ovarian Cancer16 studies
- Colorectal Cancer15 studies
- Endometrial Cancer15 studies
- Breast Cancer12 studies
- Cancer (all types)11 studies
- Triple-Negative Breast Cancer8 studies
- Atrial Fibrillation7 studies
- Lung Cancer7 studies
- Pancreatic Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.